Key result
Rituximab infusion linked to acute severe non-ischemic cardiomyopathy with ~30% LVEF.
Why the study?
The detailed cardiotoxicity profile and effects of rituximab on cardiac function were not well described.
Case Report (n=1)
Rituximab treatment may be associated with the development of severe, persistent non-ischemic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May warrant cardiac monitoring during rituximab infusion; leaves open the true incidence and mechanisms in off-label autoimmune settings.
Rituximab is an anti-CD20 monoclonal antibody frequently used for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis. In addition, rituximab has recently been increasingly used as an off-label treatment in a number of inflammatory and systemic autoimmune diseases. It is advised that rituximab infusion may cause infusion reactions and adverse cardiac effects including arrhythmia and angina, especially in patients with prior history of cardiovascular diseases. However, its detailed cardiotoxicity profile and effects on cardiac function were not well described. We report a 51-year-old man who developed non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. The patient experienced reduced cardiac functions within 48 hours after the initial infusion, which remained markedly reduced at 9-month follow-up. As the utility of rituximab expands, physicians must be aware of this serious cardiovascular adverse effect.
No takes yet. Share an insight, caveat, or question.
Cheungpasitporn et al. (2016) conducted a case report in Membranous nephropathy (n=1). Rituximab was evaluated on Development of non-ischemic cardiomyopathy. A 51-year-old man developed severe non-ischemic cardiomyopathy with a reduced ejection fraction of 30% within 48 hours of receiving his first rituximab infusion for membranous nephropathy.
Synapse has enriched 10 related papers. Consider them for comparative context: